The Infected Blood Compensation Authority (IBCA) has initiated the publication of detailed figures regarding compensation for victims of the infected blood scandal in the UK.
This move is part of the IBCA’s commitment to transparency and ensuring that those affected receive the support they need.
The IBCA will regularly update the public on the number of invites sent, claims processed, and offers of compensation made. This transparency is crucial in maintaining trust and ensuring the efficient operation of the compensation scheme.
Compensation Scheme Overview
The Infected Blood Compensation Scheme, set to be delivered by the IBCA, is designed to provide financial compensation to both infected and affected persons. The scheme includes payments for those infected with HIV, acute or chronic hepatitis C, and chronic hepatitis B, as well as their families and carers.
The compensation amounts vary based on the severity of the infection and its impact on the individual’s life, with illustrative payments ranging from £985,000 to £1.5 million for severe conditions like liver cancer and cirrhosis.
Victims and their Families
The scheme’s design reflects the recommendations of the Infected Blood Inquiry and aims to deliver compensation swiftly and with minimal delay. It ensures that compensation payments are exempt from income, capital gains, and inheritance tax and do not affect eligibility for means-tested benefits.
This approach is intended to provide comprehensive support to victims and their families, acknowledging the significant social and financial impacts of the infected blood scandal.
Metrics and Transparency
| Category | Compensation Range |
|---|---|
| People with Hepatitis C and liver cancer | £1.4m – £1.5m |
| People with cirrhosis | £985,000 – £1,130,000 |
| Interim compensation payment | £210,000 |
Expert Insight
“The compensation scheme is a significant step towards justice and support for the victims of the infected blood scandal. It reflects our commitment to transparency and fairness,”
– Sir Robert Francis KC, Interim Chair of the IBCA
This statement underscores the IBCA’s dedication to ensuring that the compensation process is both fair and transparent, aligning with the recommendations of the Infected Blood Inquiry.
Current and Future Goals
- The IBCA expects to begin making payments to infected persons by the end of 2024 and to affected persons in 2025.
- The scheme will remain open to applications until 31 March 2031 for those diagnosed before 1 April 2025, and for 6 years from the date of diagnosis for those diagnosed after 1 April 2025.
Closing Thoughts
The publication of compensation figures by the IBCA marks a significant milestone in the UK’s efforts to address the infected blood scandal. We inform and support victims and their families throughout the compensation process through transparent practices.
As the scheme continues to evolve, it remains a crucial step towards providing justice and financial support to those affected.
For more information and updates, individuals can sign up to the IBCA’s mailing list or visit the IBCA inquiry website.
